ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2024
Surveillance of low-grade appendiceal mucinous neoplasms for progression to pseudomyxoma peritonei: Results from a structured surveillance programme.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Review
- Low-Grade Appendiceal Mucinous Neoplasm Presenting as an Appendiceal Mucocele: A Case Report.Cureus · 2026Article
- The clinical and pathological features of low-grade appendiceal mucinous neoplasm (LAMN).Discover oncology · 2026Article
- Article
- Proposed strategy after complete LAMN (low-grade appendiceal mucinous neoplasm) resection by different RENAPE units: need for a new consensus?Pleura and peritoneum · 2026Article
- Beyond the Inflamed Appendix: Low-Grade Appendiceal Mucinous Neoplasm-Emphasis on Macroscopic Findings.Diagnostics (Basel, Switzerland) · 2026Article
- Low-grade appendiceal mucinous neoplasm vs. high-grade appendiceal mucinous neoplasm: similarities, differences, and current management challenges.Contemporary oncology (Poznan, Poland) · 2026Review
- Article
- Bilateral pulmonary parenchymal metastasis from a low-grade appendiceal mucinous neoplasm.Journal of surgical case reports · 2025Article
- Case Report: Lumbar herniation of a low-grade appendiceal mucinous neoplasm mimicking a chronic abscess.Frontiers in oncology · 2025Article
- Low Grade Appendiceal Mucinous Neoplasm - A Case Series A Silent Threat with Deadly Consequences.Iranian journal of pathology · 2025Article
- Surveillance of low-grade appendiceal mucinous neoplasms for progression to pseudomyxoma peritonei: Results from a structured surveillance programme.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimLow-grade appendiceal mucinous neoplasm (LAMN) of the appendix is a rare tumour that can progress to pseudomyxoma peritonei (PMP). There is a lack of standardization of surveillance following resection of LAMN as the progression rate to PMP is unclear. The aim of this study was to evaluate the rate of progression following resection of LAMN to PMP in a structured surveillance programme.
methodData for all patients referred for LAMN surveillance from 2013 to 2021 were retrospectively collected. The surveillance regime consisted of annual CT and tumour markers for a 5-year period. Patients who progressed to PMP were identified.
resultsOf the patients enrolled in surveillance following appendicectomy and LAMN diagnosis (65.1% female, median age 56 years), 83 had completed at least 1 year of surveillance (median follow-up 24 months). Of these, 6% (n = 5) showed disease progression during follow-up. The median time to progression was 23 months. Survival analysis revealed no statistically significant difference in progression with regards to T staging (p = 0.39), margin positivity (p = 0.11) or appendiceal perforation (p = 0.26). No patients with Tis disease developed PMP. A statistically significant difference in progression was seen in patients with M1b staging (p = 0.021) and in those with mucin beyond the right iliac fossa at diagnosis (p = 0.04).
conclusionThe observed progression rate justifies the necessity of postappendicectomy surveillance in patients with LAMN, with the risk of progression being highest within the first 3 years of diagnosis. The described surveillance programme allows for early detection of subclinical progression to PMP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.